MARK MCANDREW is a partner in the Health & Life Sciences and Business and Finance Groups in Taft’s Cincinnati office.  He concentrates his practice on corporate, transactional and regulatory matters, counseling a wide variety of clients ranging from start-up entities to Fortune 500 companies, including drug manufacturers, health technology companies, hospitals, physicians, pharmacies, nursing homes and consumer product manufacturers, to name a few.

In addition to working on mergers and acquisitions and other general corporate matters, a particular emphasis of Mr. McAndrew’s practice involves providing strategic legal advice to clients navigating complex transactional and regulatory health care issues, such as the Medicare and Medicaid programs; anti-kickback, false claims and other fraud and abuse counseling; reimbursement and compliance audits; FDA and DEA requirements and health care information technology matters.  He has extensive transactional experience with both brand and generic pharmaceutical manufacturers, including product development issues, licensing deals, manufacturing, distribution and supply arrangements, advertising and promotional compliance, rebate agreements, PBM and managed care plan contracting, good manufacturing practices and other quality issues.      

He also has experience in government contract and procurement matters, and has worked extensively with clients to help them do business with federal, state and county administrative services and purchasing agencies, including municipal corporations, school districts and educational institutions. In particular, he has advised clients in joint venture issues, teaming and subcontractor agreements and other contract negotiations, and has assisted clients with other pre-bid matters such as reviewing, analyzing and responding to invitations to bid, RFPs, RFQs, and solicitations. He has also counseled clients with respect to post-award matters, including compliance counseling, agency audits, award protests, requests for equitable adjustments and False Claims Act investigations.